Phillips E H, Hodson A, Hermine O, Bazarbachi A, Cwynarski K
Department of Haematology, University College Hospital, London, UK.
Department of Haematology, Ipswich Hospital, Ipswich, UK.
Bone Marrow Transplant. 2016 Dec;51(12):1549-1555. doi: 10.1038/bmt.2016.154. Epub 2016 Sep 12.
Adult T-cell leukaemia/lymphoma (ATL) is an aggressive HTLV-1-related malignancy, rare outside of regions where the retrovirus is endemic. Although the use of antiviral therapy has improved outcomes, particularly for indolent forms of ATL, response to combination chemotherapy is poor and outcomes for aggressive subtypes remains dismal. Consolidation with allogeneic stem cell transplant (alloSCT) has an increasing role in the management of ATL in eligible patients, offering favourable long-term remission rates. However, relatively high-transplant-related mortality and issues with donor recruitment for certain ethnicities remain problematic. In this review, we discuss the rationale for and issues surrounding alloSCT in ATL in the context of conventional and emerging therapies.
成人T细胞白血病/淋巴瘤（ATL）是一种与人类嗜T淋巴细胞病毒1型（HTLV-1）相关的侵袭性恶性肿瘤，在该逆转录病毒流行地区以外较为罕见。尽管抗病毒治疗的应用改善了治疗效果，尤其是对于惰性形式的ATL，但联合化疗的反应较差，侵袭性亚型的治疗结果仍然不佳。异基因干细胞移植（alloSCT）巩固治疗在符合条件的ATL患者管理中的作用日益增加，可提供良好的长期缓解率。然而，相对较高的移植相关死亡率以及某些种族供体招募问题仍然存在。在本综述中，我们在传统和新兴疗法的背景下讨论了ATL中alloSCT的理论依据和相关问题。
